Your session is about to expire
← Back to Search
Other
ICP-723 for Advanced Cancer
Phase 1
Waitlist Available
Led By Jun Zhang
Research Sponsored by InnoCare Pharma Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1.5 years.
Awards & highlights
Study Summary
This trial is testing a new drug for people with cancer who have no other options. They will test how well the drug works and if it has any side effects.
Who is the study for?
Adults aged 18-80 with advanced solid tumors that can't be removed or have spread and don't respond to standard treatments may join. They should have measurable tumors, adequate organ function, and stable brain tumors if present. Those with significant digestive/neurological issues, recent major surgery, uncontrolled diseases, heart problems, or other active cancers in the last 5 years are excluded.Check my eligibility
What is being tested?
The trial is testing ICP-723's safety and how the body processes it in patients whose solid tumors haven't responded to standard care. It involves gradually increasing doses to find a safe level while monitoring participants' reactions.See study design
What are the potential side effects?
While specific side effects of ICP-723 aren't listed here, common ones for cancer drugs include nausea, fatigue, risk of infection due to low blood cell counts, liver or kidney function changes; detailed risks will be monitored throughout the study.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 1.5 years.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1.5 years.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence and severity of dose-limiting toxicity (DLT), adverse events (AEs), and serious adverse events (SAEs). Frequency of dose interruptions, reductions and intensity
Secondary outcome measures
Apparent clearance (CL/F)
Apparent volume of distribution (Vz/F)
Area under the plasma concentration-time curve (AUC0-∞ and AUC0-t)
+5 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: ICP-723Experimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
InnoCare Pharma Inc.Lead Sponsor
3 Previous Clinical Trials
570 Total Patients Enrolled
Jun ZhangPrincipal InvestigatorUniversity of Kansas Medical / Cancer Centers
4 Previous Clinical Trials
4,841 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My cancer is advanced, cannot be surgically removed, and has not responded to standard treatments.I haven't had cancer treatment, except oral chemo, in the last 4 weeks or 5 half-lives.My organs are functioning well enough for treatment.I am between 18 and 80 years old.I haven't had major surgery in the last 4 weeks or minor surgery in the last 2 weeks.I have no major stomach or nerve issues affecting medication absorption.I have heart disease that is not well-managed.I have a stable brain tumor or metastases, with no symptoms.I have had no other cancers in the last 5 years, except for those considered cured and local.
Research Study Groups:
This trial has the following groups:- Group 1: ICP-723
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Has the FDA accepted ICP-723 for public use?
"ICP-723's safety is rated as a 1 on our scale, due to it only being in its initial phase of clinical trials and not having much supporting data for efficacy or safety."
Answered by AI
Are there any open enrollments for this experiment?
"As per the clinicaltrials.gov database, this medical trial is currently recruiting suitable individuals and has been since July 30th 2021 (last edited October 8th 2022)."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger